Home  /  Resource Library  /  Venetoclax-rituximab +/- bendamustine vs bendamustine-rituximab in relapsed/refractory follicular lymphoma: CONTRALTO

Venetoclax-rituximab +/- bendamustine vs bendamustine-rituximab in relapsed/refractory follicular lymphoma: CONTRALTO

Results of a phase 2 trial invesitgating venetoclax combined with rituximab and bendamustine for treatment of relapsed follicular lymphoma. (Abstract only)